A review of advances in the use of the GnRH agonist deslorelin in control of reproduction.
The prevention of breeding in animals using GnRH analogues has been the object of research over many years. Recently, a new drug delivery formulation was developed which enabled the development of products that could be commercialised for veterinary use. The formulation has now been approved in certain countries for use in male dogs, and applications are being expanded to cover repeat usage, extended duration, use in females, other indications and other animal species. With respect to repeat usage, dogs have been re-implanted for four consecutive doses and monitored until they returned to normal steroidogenesis. All dogs returned to normal steroidogenesis following cessation of treatment. In females, it was previously shown that implanted bitches with progesterone < 5 ng/mL at the time of implantation had an induced estrus. In a new study at Chulalongkorn University, implanting female pups at around 4 mo prevented this occurrence, whereas implantation at 7 mo did not.
Trigg
T E
TE
Peptech Animal Health, Locked Bag 2053, Macquarie Park, NSW 2113, Australia. trigg@peptech.com
Doyle
A G
AG
Walsh
J D
JD
Swangchan-uthai
T
T
D000818:Animals; D003270:Contraceptive Agents / Q000494:pharmacology*; D004285:Dogs / Q000502:physiology*; D004343:Drug Implants; D004971:Estrus / Q000187:drug effects* / Q000502:physiology; D005260:Female; D008297:Male; D012098:Reproduction / Q000187:drug effects; D013739:Testosterone / Q000097:blood; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives* / Q000494:pharmacology
D003270:Contraceptive Agents; D004343:Drug Implants; D017329:Triptorelin Pamoate; D013739:Testosterone; C066438:deslorelin